Skip to main content

Table 3 Baseline characteristics of the randomized controlled trial population (mild and moderate myocardial iron loading) vs. open-label combination therapy population (severe myocardial iron loading). Values and abbreviations presented as in table 1.

From: Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major

  Mild-moderate siderosis Severe siderosis p-value
  RCT Longitudinal trial  
Number 65 15 -
Age (years) 28.8 ± 4.7 27.8 ± 4.8 0.5
Gender (male) 27 (41.5%) 6 (40.0%) 0.9
Body surface area 1.55 ± 0.15 1.56 ± 0.13 0.8
Heart rate 79 ± 13 97 ± 18 < 0.01
Deferoxamine (mg/kg/day) 40.6 ± 13.5
(5 days/week)
40.7 ± 12.0
(5 days/week)
0.9
CMR measures    
Myocardial T2* 12.0 (0.13) 6.0 (0.09) N/A
Liver T2* 4.5 (0.57) 2.9 (0.67) 0.06
RVEDV (mL) 130.7 ± 32.4 146.7 ± 35.1 0.2
RVESV (mL) 52.4 ± 17.8 76.5 ± 27.6 < 0.01
RVEF (%) 60.6 ± 7.1 49.0 ± 9.4 < 0.01
Echo measures    
PAP (mmHg) 21.6 ± 5.2 22.0 ± 5.9 0.8
Blood measures    
Hepatitis C positive 49 (75%) 11 (73%) 0.9
Serum ferritin (μg/L) 1472 (0.11) 2057 (0.08) 0.1
BNP (pmol/L) 15.0 (7.1, 28.8) 26.0 (15.6, 40.5) 0.01
Cardiac medication    
Any 13 (20%) 7 (47%) 0.03
Digoxin 7 (11%) 4 (27%) 0.1
ACEi/ARB 13 (20%) 7 (47%) 0.03
Diuretics 8 (12%) 4 (27%) 0.2